Triple Negative Breast Neoplasms

Updated Efficacy Data of Ivonescimab Plus Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025

8 hours ago talkbio0Tagged AK112 - 308, Breakthrough Therapy Designation, Combined, Complex partial seizures, disease control rate, ESMO IO, First line treatment, Frequency of Responses, HARMONi-BC1, Ivonescimab, PD-1/VEGF bispecific antibody, PD-L1, Pharmacotherapy, Phase 2 Clinical Trials, Progression-Free Survival, safety profile, Subgroup A Nepoviruses, TNBC, Triple Negative Breast Neoplasms, Yidafan

ivonescimab; Yidafan; PD-1/VEGF bispecific antibody; triple-negative breast cancer; TNBC; first-line treatment; ESMO IO 2025; Phase II trial; chemotherapy combination; objective response rate; progression-free survival; disease control rate; PD-L1 CPS subgroups; safety profile; Breakthrough Therapy Designation; HARMONi-BC1; AK112-308

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig in Advanced Triple-Negative Breast Cancer

2 days ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, BREAST-01, disease control rate, Gene Expression, Myers Squibb, ORR, PD-L1, PD-L1xVEGF-A, Phase 2 trial, Progression-Free Survival, pumitamig, ROSETTA, SABCS, TNBC, Triple Negative Breast Neoplasms

BioNTech; Bristol Myers Squibb; pumitamig; BNT327; PD-L1xVEGF-A bispecific antibody; Phase 2 trial; triple-negative breast cancer; TNBC; confirmed ORR; disease control rate; progression-free survival; PD-L1 expression; ROSETTA BREAST-01; SABCS

ESMO Spotlight: Flagship ADCs move into early-stage cancer to validate chemo-displacement ambitions

2 months ago talkbio0Tagged 2025, ADCs, Administration occupational activities, Antibody-Drug Conjugates, Biological Markers, chemo-displacement, Datopotamab deruxtecan, Datroway, Enhertu, ESMO, HER2-positive, Limited stage (cancer stage), Malignant neoplasm of breast, Toxicity aspects, trastuzumab, Triple Negative Breast Neoplasms

ESMO 2025; antibody-drug conjugates; ADCs; early-stage cancer; chemo-displacement; trastuzumab deruxtecan; ENHERTU; datopotamab deruxtecan; DATROWAY; breast cancer; HER2-positive; triple-negative breast cancer; biomarkers; toxicity management

AstraZeneca Furthers Ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO 2025

2 months ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, cancer care, Datopotamab deruxtecan, Datroway, Deruxtecan, durvalumab, Enhertu, ESMO, Imfinzi, Malignant neoplasm of stomach, Malignant neoplasm of urinary bladder, Neoplasms, Overall Survival, trastuzumab, trials, Triple Negative Breast Neoplasms

AstraZeneca; ESMO 2025; cancer care; pivotal trials; oncology; Datopotamab deruxtecan (Datroway); Enhertu (trastuzumab deruxtecan); Imfinzi (durvalumab); triple-negative breast cancer; bladder cancer; gastric cancer; overall survival; antibody-drug conjugates

AstraZeneca and Daiichi Sankyo Report Landmark Results for Datroway in Triple-Negative Breast Cancer

2 months ago talkbio0Tagged ADC, AstraZeneca, Clinical Trials, Daiichi, Datopotamab deruxtecan, Datroway, Immunotherapy, Overall Survival, Pharmacotherapy, Phase 3 trial, Sankyo, therapeutic autologous dendritic cells, Triple Negative Breast Neoplasms, TROPION-Breast02

Datroway; Datopotamab deruxtecan; triple-negative breast cancer; ADC; AstraZeneca; Daiichi Sankyo; clinical trial; overall survival; chemotherapy; TROP2; phase 3 trial; immunotherapy; TROPION-Breast02

Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win

6 months ago talkbio0Tagged Antibody-Drug Conjugates, Combined Modality Therapy, Gilead Sciences, Immunotherapy, Keytruda, Phase 3 trial, practice-changing, Progression-Free Survival, TNBC, Triple Negative Breast Neoplasms, Trodelvy

Gilead Sciences; Trodelvy; Keytruda; triple-negative breast cancer; TNBC; antibody-drug conjugate; immunotherapy; progression-free survival; ASCO 2025; phase 3 trial; practice-changing; combination therapy

Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal

8 months ago talkbio0Tagged Keytruda, Metastatic to, Overall Survival, Triple Negative Breast Neoplasms, Trodelvy

Trodelvy, Triple Negative Breast Neoplasms, Metastatic to, Keytruda, Overall Survival

AstraZeneca’s Truqap Combo Fails to Improve Survival in Phase III Triple-Negative Breast Cancer Trial

1 year ago talkbio0Tagged AKT1 protein, human, AstraZeneca, CAPItello-290, capivasertib, Overall Survival, paclitaxel, Phase 3 Clinical Trials, PIK3CA gene, PTEN gene, Triple Negative Breast Neoplasms, Truqap

AstraZeneca, Truqap, capivasertib, Phase III trial, triple-negative breast cancer, CAPItello-290, paclitaxel, overall survival, PIK3CA, AKT1, PTEN

Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy

2 years ago talkbio0Tagged Adenocarcinoma of lung (disorder), Antigens, Biosciences, Cancer Therapeutic Procedure, Cartography, Cervical Atlas, Drug Development, Gilead Sciences, Neoplasms, summit, targets, Technology Platform, Triple Negative Breast Neoplasms

Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.